$SION News

Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program - Slideshow

Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Sionna's SION-719 Failure Changes Everything (Rating Downgrade)

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Guggenheim Downgrades Sionna Therapeutics to Neutral

Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5

Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript